<乌鸦传媒>Neratinib-Based Combo Shows Efficacy in HR+, HER2-Mutant Metastatic Breast Cancer Objective response rate of 42% in patients previously treated with CDK4/6 inhibitors Dec 12, 2021
<乌鸦传媒>Novel Bispecific Antibody Nets Durable Remissions in Follicular Lymphoma Mosunetuzumab offers "clinically meaningful outcomes" in relapsed/refractory disease Dec 12, 2021
<乌鸦传媒>Induction Isatuximab-RVd Combo Boosts MRD Negativity in Multiple Myeloma Half of newly diagnosed, transplant-eligible patients reached minimal residual disease negativity Dec 12, 2021
<乌鸦传媒>CAR T-Cell Therapy Makes Strong Case for Earlier Use in Lymphoma Large increases in event-free survival with two CAR T-cell products in second line Dec 11, 2021
<乌鸦传媒>Upfront IDH1 Inhibitor Triples Survival in Older AML Median OS for ivosidenib-azacitidine reached 2 years in patients ineligible for intensive therapy Dec 11, 2021
<乌鸦传媒>Case of Parkinson's-Like Symptoms in Myeloma Patient After CAR-T Product FDA advises monitoring patients after T-cell infusion for signs, symptoms of neurotoxicity Dec 10, 2021
<乌鸦传媒>'Watch and Switch' Strategy Extends PFS in HR-Positive Breast Cancer Progression-free survival doubled with treatment change based on monitoring for resistance marker Dec 10, 2021
<乌鸦传媒>CDK7 Inhibitor-Based Combo Promising in CDK4/6-Resistant Breast Cancer Clinical benefit rate of 36%, plus tumor shrinkage, with samuraciclib plus fulvestrant Dec 10, 2021
<乌鸦传媒>Pyrotinib Tops Lapatinib in Metastatic HER2-Positive Breast Cancer Updated PHOEBE trial results now show an overall survival benefit as well Dec 10, 2021
<乌鸦传媒>Ethics Consult: Should Doctor Inform Patient's Family of Diagnosis? MD/JD Weighs In You voted, now see the results and an expert's discussion Dec 10, 2021
<乌鸦传媒>Benefits of Ovarian Suppression Persist in Premenopausal Breast Cancer Aromatase inhibitor-ovarian suppression tops tamoxifen strategies at 12-13 years Dec 09, 2021
<乌鸦传媒>Highly Mutated Breast Cancer Responds to Immunotherapy Nivolumab-ipilimumab combination associated with durable response in small study Dec 09, 2021
<乌鸦传媒>Ribociclib's OS Benefit in Breast Cancer Seen Regardless of Metastatic Site Second analysis shows OS benefit consistent across some intrinsic subtypes as well Dec 09, 2021
<乌鸦传媒>No Benefit With Metformin in Early Breast Cancer, Regardless of ER/PR Status However, there could be improved outcomes in HER2-positive patients Dec 08, 2021
<乌鸦传媒>Small PFS Boost With HDAC Inhibitor for Advanced HR-Positive Breast Cancer Chinese study contradicts U.S. trial that showed no benefit with entinostat add-on Dec 08, 2021
<乌鸦传媒>Black Women Most at Risk for Post-Surgical Lymphedema Black women seemed to have triple the odds of swelling after axillary lymph node dissection Dec 08, 2021
<乌鸦传媒>TROP2-Directed ADC Promising in Advanced Triple-Negative Breast Cancer Datopotamab deruxtecan turns in solid phase I results Dec 08, 2021
<乌鸦传媒>BRAF Inhibition in Pediatric Ameloblastoma of the Jaw Targeted therapy in 3 boys allowed for conservative surgery to restore jaw to predisease state Dec 07, 2021
<乌鸦传媒>Hemostatic Powder on Par for Stopping Acute Upper GI Bleeds In non-inferiority trial, TC-325 matched standard therapy for nonvariceal lesions Dec 07, 2021
<乌鸦传媒>Genomic Profiling Improves Outcomes in Breast Cancer PFS was better when targeted treatment for genomic alterations was supported by ESCAT criteria Dec 07, 2021
<乌鸦传媒>But the Cancer Was 'Indolent' Tread carefully when offering patients an optimistic outlook Dec 07, 2021
<乌鸦传媒>Novel Endocrine Drug Slows Previously Treated HR-Positive Breast Cancer Elacestrant led to significant improvement in all patients, ESR1-mutant subgroup Dec 07, 2021
<乌鸦传媒>Novel Chemoimmunotherapy Regimen Wows in Pediatric Neuroblastoma "I've never seen anything like this," researcher says of 3-year event-free survival rate Dec 06, 2021
<乌鸦传媒>Bevacizumab Add-On No Help in Progressive EGFR-Mutant Lung Cancer Single-agent osimertinib prevails in progressive, T790M-positive NSCLC Dec 02, 2021
<乌鸦传媒>Artificial Intelligence Tool Gets High Marks in Reading Mammograms Breast cancer screening results show AI's mettle in real-world dataset Dec 02, 2021
<乌鸦传媒>States Didn't Follow CDC Recs to Prioritize COVID Vaccine for Cancer Patients Only 17 states gave cancer patients the same immunization priority as those ages 65-74 Dec 02, 2021
<乌鸦传媒>Long-Term Data Reinforce Standard of Care in Unresectable Melanoma Landmark trial shows median OS of 72.1 months with nivolumab-ipilimumab Dec 01, 2021
<乌鸦传媒>NCCN Reverses on Guideline Change for Surveillance in Prostate Cancer Active surveillance again preferred choice for "most" men with low-risk disease Dec 01, 2021
<乌鸦传媒>Next-Gen MRD Testing Predicts Acute Leukemia Relapse After CAR-T Nearly all patients with detectable disease relapsed or progressed to transplant, other therapies Dec 01, 2021
<乌鸦传媒>Chemo-Free Regimen Highly Active in Older Mantle Cell Lymphoma Patients Overall response rate of 96% with ibrutinib-rituximab, but cardiotoxicity a possible issue Nov 29, 2021
<乌鸦传媒>Novel Triplet Yields Undetectable MRD Status in 90% of CLL/SLL Patients Zanubrutinib plus obinutuzumab and venetoclax was also well tolerated Nov 29, 2021
<乌鸦传媒>'Actual' 5-Year Survival Rate of 27% After Surgery, Chemo for Pancreatic Cancer Fewer than half of the survivors remained recurrence- or disease-free Nov 19, 2021
<乌鸦传媒>Year in Review: Prostate Cancer PSMA-targeted imaging agent approvals, MRI-targeted biopsies, and genomic testing Nov 19, 2021
<乌鸦传媒>FDA OKs PD-1 Inhibitor for Adjuvant Treatment of Kidney Cancer Key trial showed 32% reduction in risk of recurrence with pembrolizumab Nov 18, 2021
<乌鸦传媒>Ceritinib Shows Promise in ALK-Positive Pediatric Malignancies Responses seen in neuroblastoma, among other tumors Nov 17, 2021
<乌鸦传媒>Tumor Spill Common in Minimally Invasive Hysterectomies for Endometrial Cancer Few surgeons in survey reported changing post-op management after spillage Nov 16, 2021
<乌鸦传媒>Year in Review: HER2-Positive Breast Cancer ADCs impress in second-line therapy, primary surgery debate, neoadjuvant PD-L1 falls short Nov 15, 2021
<乌鸦传媒>Pegylated Interferon Wins FDA Approval for Polycythemia Vera Majority of patients attained complete hematologic response with ropeginterferon alfa-2b Nov 15, 2021
<乌鸦传媒>Chemo-ICI Combo Promising in Soft Tissue Sarcoma PFS rate of 69% at 12 weeks in liposarcoma patients with eribulin and pembrolizumab Nov 14, 2021
<乌鸦传媒>Active Surveillance Still the Best Bet in Desmoid-Type Fibromatosis GRAFITI trial show's less than a third of watched patients eventually need active treatment Nov 13, 2021
